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The present paper summarizes the preclinical and clinical studies conducted to
define the “anti-alcohol” pharmacological profile of the prototypic GABAB receptor
agonist, baclofen, and its therapeutic potential for treatment of alcohol use disorder
(AUD). Numerous studies have reported baclofen-induced suppression of alcohol
drinking (including relapse- and binge-like drinking) and alcohol reinforcing, motivational,
stimulating, and rewarding properties in rodents and monkeys. The majority of clinical
surveys conducted to date—including case reports, retrospective chart reviews, and
randomized placebo-controlled studies—suggest the ability of baclofen to suppress
alcohol consumption, craving for alcohol, and alcohol withdrawal symptomatology in
alcohol-dependent patients. The recent identification of a positive allosteric modulatory
binding site, together with the synthesis of in vivo effective ligands, represents a
novel, and likely more favorable, option for pharmacological manipulations of the GABAB
receptor. Accordingly, data collected to date suggest that positive allosteric modulators
of the GABAB receptor reproduce several “anti-alcohol” effects of baclofen and
display a higher therapeutic index (with larger separation—in terms of doses—between
“anti-alcohol” effects and sedation).
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INTRODUCTION
Alcohol abuse and dependence are severe mental disorders char-
acterized by bouts of compulsive and uncontrolled alcohol con-
sumption, and an inability to cut down drinking despite the
knowledge of its negative consequences (American Psychiatric
Association, 2000). These frequent disorders are related to
chronic medical conditions, car crashes, domestic violence, fetal
alcohol syndrome, neuropsychological impairment, economic
costs, loss of productivity, and psychiatric comorbidity (see Rehm
et al., 2009; Nutt et al., 2010). Up to the penultimate edition of
the Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV-TR) (American Psychiatric Association, 2000), alcohol abuse
and dependence were classified as independent alcohol use disor-
ders (AUDs); in the last DSM edition (DSM-5), they have been
joined into a single mental disorder, alcohol use disorder, or AUD
(American Psychiatric Association, 2013). Diagnostic criteria for
AUD include those listed for the diagnosis of dependence and
abuse, together with a new criterion, a subjective experience of
wanting to consume alcohol, also defined “craving” (Tiffany and
Wray, 2012).
The aims of AUD treatment consist in achieving abstinence,
or reducing alcohol consumption, reducing the frequency and
severity of relapses, and improving psychological and social
functioning. The process involved in acquiring and maintain-
ing abstinence from alcohol may require a first phase known
as “detoxification” aimed at decreasing withdrawal symptoms
(when present), and a second “rehabilitation” phase, aimed at
maintaining themotivation to abstain, developing an alcohol-free
lifestyle, and reducing the risk of relapse. Treatment to achieve
these aims includes psychological and pharmacological thera-
pies. Psychological and social interventions (including Alcoholics
Anonymous and various counseling approaches) are usually con-
sidered core treatment options (see Schuckit, 2009). However,
these approaches have demonstrated only amoderate success rate.
Pharmacotherapy should be used to increase the efficacy of non-
pharmacological approaches. Unfortunately, the few available
AUD medications display only moderate efficacy, with several
limitations to their clinical use, including poor compliance and
even abuse liability (see Chick and Nutt, 2012; see Franck and
Jayaram-Lindström, 2013).
Over the last 15 years, multiple lines of experimental and clin-
ical evidence have suggested a role for the GABAB receptor in
the control of several alcohol-related behaviors (for reviews on
the GABAB receptor, see Bettler et al., 2004; Couve et al., 2004;
Emson, 2007). Pharmacological activation of the orthosteric
binding site of the GABAB receptor has repeatedly been reported
to suppress alcohol drinking and alcohol withdrawal syndrome
(AWS) in rodents and human alcoholics, as well as alcohol rein-
forcing and motivational properties in rodents and non-human
primates and craving for alcohol in human alcoholics. These
data have led to the development of the prototypic GABAB
receptor agonist, baclofen (used for more than 50 years in the
treatment of spasticity), as a promising, novel pharmacotherapy
for AUD.
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More recently, identification of a binding site of positive
allosteric modulation (topographically distinct from the orthos-
teric binding site) has provided a new strategy for pharmacolog-
ical manipulation of the GABAB neurotransmission. Activation
of this binding site—by a class of agents known as positive
allosteric modulators of the GABAB receptor (GABAB PAMs)—
augments the affinity of the GABAB receptor for GABA and
agonists and synergistically potentiates their effects (see Froestl,
2010). GABAB PAMs are devoid of substantial intrinsic ago-
nistic activity in the absence of GABA; they do not perturb
receptor signaling on their own, but potentiate the effect of
GABA only in those synapses where and when endogenous
GABA has been released (see Froestl, 2010). Accordingly, GABAB
PAMs are expected to produce fewer side effects and lower tol-
erance. Rodent data confirm that GABAB PAMs reproduced
several in vivo effects of baclofen, displaying a notably larger
separation between the “desired” pharmacological effects (e.g.:
anxiolysis, “anti-addictive” effects) and “unwanted,” or adverse,
effects (e.g., sedation, motor-incoordination). For these reasons,
GABAB PAMs currently represent a major step forward in the
pharmacology of the GABAB receptor.
The present paper is aimed at reviewing the lines of preclini-
cal and clinical evidence featuring baclofen and GABAB PAMs as
potentially effective pharmacotherapies for AUD.
PRECLINICAL DATA
BACLOFEN
The vast majority of data presently available have been col-
lected with baclofen; some of these results have subsequently been
reproduced with additional GABAB receptor agonists, including
CGP44532 and SKF97541 (also known as CGP35024).
Acquisition of alcohol drinking
A first set of studies investigated the effect of acute or repeated
administration of baclofen on alcohol intake in rats or mice
exposed to the conventional, homecage 2-bottle “alcohol vs.
water” choice regimen. Under this experimental procedure, ani-
mals are exposed to the choice between a relatively low con-
centrated alcohol solution (usually 10%, v/v) and water and
freely allowed to consume alcohol. This procedure —largely used
because of its relative simplicity—provides information on the
mere consumption of alcohol. It possesses however considerable
predictive validity, especially when applied to rats selectively bred
for high alcohol preference and consumption.
When repeatedly (once daily for 10 consecutive days) admin-
istered over the initial period of exposure to alcohol, baclofen
(1–3mg/kg, i.p.) has been reported to completely block the acqui-
sition of alcohol drinking behavior in selectively bred, Sardinian
alcohol-preferring (sP) rats (Colombo et al., 2002). Acquisition
of alcohol drinking occurred only once treatment with baclofen
had been interrupted. These data suggest that activation of the
GABAB receptor effectively blocked discovery and experience of
those psychopharmacological effects of alcohol that sustain alco-
hol drinking behavior in sP rats. Reduction in alcohol intake was
associated to a compensatory increase in daily water intake, so
that total daily fluid intake remained unchanged; these data sug-
gest the selectivity of baclofen effect on alcohol intake and lead
to reasonably exclude that the suppressing effect of baclofen on
alcohol intake was secondary to possible motor-incapacitating
or sedative effects (that would disrupt the normal rates of
drinking).
These data have subsequently been replicated with CGP44532:
its repeated administration (0.03–1mg/kg, i.p., once daily for
10 consecutive days) completely blocked acquisition of alcohol
drinking in sP rats (Colombo et al., 2002).
Maintenance of alcohol drinking
More numerous studies have investigated the effect of baclofen
on alcohol intake in alcohol-experienced rats (i.e., rats in which
the consumption of pharmacologically relevant doses of alcohol
was already well consolidated before the start of treatment with
baclofen; these alcohol-experienced rats are thought to model
the “maintenance” or “active drinking” phase of human alcohol
dependence). Acute or repeated (once daily for 4–14 consecu-
tive days) administration of doses of baclofen ranging between 1
and 10mg/kg (i.p.) suppressed, in a dose-related fashion, alcohol
intake in selectively bred sP (Colombo et al., 2000) and University
of Chile bibulous (UChB) (Quintanilla et al., 2008) rats, unse-
lected Long Evans (Daoust et al., 1987; see however Smith et al.,
1999) and Wistar (Stromberg, 2004) rats, and C57BL/6N (Peters
et al., 2013) and Swiss (Villas Boas et al., 2012) mice. These results
suggest the ability of baclofen to decrease alcohol intake in rats
and mice displaying consolidated and relatively high levels of
alcohol consumption.
Alcohol deprivation effect
Additional studies used the free-choice regimen to investigate the
effect of treatment with baclofen in a rodent model of alcohol
relapse named “alcohol deprivation effect” (ADE). ADE is defined
as the temporary increase in voluntary alcohol intake—often
doubling the regular intake—occurring after a period of forced
abstinence, or deprivation, from alcohol (see Martin-Fardon and
Weiss, 2013). An initial study (Colombo et al., 2003a) employed
the 2-bottle “alcohol (10%, v/v) vs water” choice regimen and
found that acute administration of baclofen (1-3mg/kg, i.p.) to
sP rats previously deprived of alcohol for 7 consecutive days
resulted in the complete suppression of the extra amount of alco-
hol consumed during the first hour of re-access (the time period
during which ADE is maximal in sP rats). In a subsequent study
(Colombo et al., 2006), sP rats were exposed to a 4-bottle “alcohol
vs. water” choice regimen with multiple alcohol concentrations
(10, 20, and 30%, v/v). Acute injection of baclofen (1mg/kg, i.p.)
at the end of the 14-day alcohol-deprivation period resulted in the
complete suppression of both aspects of the augmented demand
for alcohol: (a) increase in the amount of alcohol consumed; (b)
shift in preference for the highest concentrated alcohol solution
(that would result in amore rapid absorption of alcohol and faster
perception of its psychopharmacological effects). Notably, in both
studies water and food intake, as well as spontaneous locomotor
activity, were not altered by baclofen treatment, suggesting that its
suppressing effect was selective for alcohol and occurred at doses
devoid of any sedative effect. Similar data have been collected with
CGP44532: its acute administration (0.03–1mg/kg, i.p.) selec-
tively blocked indeed ADE in sP rats re-exposed to alcohol after
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a 14-day period of alcohol deprivation (Carai et al., 2005). These
data suggest a role for the GABAB receptor in the neural substrate
controlling relapse-like drinking in rats.
Binge-like alcohol drinking
Baclofen has also been found to suppress alcohol intake in two
mouse models of binge drinking. The first study (Moore and
Boehm, 2009) used the experimental model Drinking in the Dark
(DID), based on the exposure of alcohol-consuming C57BL/6J
mice to daily drinking sessions of 2 h (3 h into the dark phase
of the light-dark cycle) with a single bottle containing 20% (v/v)
alcohol. Acute microinjection of baclofen (0.01 and 0.02μg) into
the anterior, but not posterior, portion of the ventral tegmen-
tal area (VTA) resulted in a marked reduction of alcohol intake.
Baclofen microinjection did not alter the intake of water or sweet-
ened water, demonstrating the drug selectivity on alcohol intake.
The second study (Tanchuck et al., 2011) used the experimental
model Scheduled High Alcohol Consumption, in whichWithdrawal
Seizure Control mice were exposed to 30-min drinking sessions
every third day with 5% (v/v) alcohol. Again, acute adminis-
tration of baclofen (2.5–5mg/kg, i.p.) markedly reduced alcohol
intake.
Operant self-administration of alcohol
Several studies have also tested the capacity of baclofen to sup-
press operant, oral alcohol self-administration in rats. Under
these procedures, alcohol is made available to rats via comple-
tion of a behavioral response (usually, responding on a lever for
a given number of times), to allow the reinforcing and moti-
vational properties of alcohol to be assessed (in addition to its
mere consumption). Operant procedures differ from the alcohol-
drinking procedures in that alcohol is not “freely” available and a
specific amount of “work” is required to access alcohol. Baclofen
has been tested under the three most commonly used proce-
dures of alcohol self-administration: (a) fixed ratio (FR) schedule
of reinforcement, in which the response requirement (RR; i.e.,
the “cost” of each alcohol presentation in terms of number of
responses on the lever) is predetermined and kept fixed through-
out the session (providing a measure of both alcohol consump-
tion and reinforcing properties of alcohol); (b) within-session
progressive ratio (PR) schedule of reinforcement, in which—over
the same single session—RR is progressively increased after the
delivery of each reinforcer, and the lowest ratio not completed
(named breakpoint) is taken as measure of motivational proper-
ties of alcohol; (c) within-session extinction responding (ER), in
which lever-responding is never reinforced: the highest number of
lever-responses (named ER) is taken as measure of motivational
properties of alcohol.
The studies using the FR (varying from FR1 to FR4) sched-
ule of reinforcement have reported that acute (often using a
Latin square design) and repeated (3 consecutive daily self-
administration sessions) treatment with baclofen (0.5–5.6mg/kg,
i.p., in rats; 1–17mg/kg, i.p., in mice) reduced both number
of lever-responses for alcohol and amount of self-administered
alcohol in (a) selectively bred alcohol-preferring sP (Maccioni
et al., 2005, 2012), Indiana P (Liang et al., 2006; Maccioni et al.,
2012), and Alko Alcohol (AA) (Maccioni et al., 2012) rats, (b)
unselected Long-Evans (Anstrom et al., 2003; Janak and Gill,
2003) and Wistar (Petry, 1997; Walker and Koob, 2007; Dean
et al., 2011) rats, and (c) C57BL/6J mice (Besheer et al., 2004). In
close agreement with this large set of data on baclofen, acute treat-
ment with SKF97541 (0.1–1mg/kg, i.p.) reduced operant alcohol
self-administration in C57BL/6J mice (Besheer et al., 2004).
Similar data were also collected in the PR and ER experiments:
treatment with baclofen (1–3mg/kg; i.p; administered using a
Latin square design) (a) reduced the breakpoint for alcohol in
sP (Maccioni et al., 2008b, 2012), P (Maccioni et al., 2012), AA
(Maccioni et al., 2012) and Wistar (Walker and Koob, 2007)
rats as well as (b) virtually completely suppressed ER in sP rats
(Colombo et al., 2003b).
Taken together, data from alcohol self-administration stud-
ies suggest that treatment with non-sedative doses of baclofen
effectively reduced—beside alcohol consumption—the reinforc-
ing and motivational properties of alcohol. Since operant proce-
dures of alcohol self-administration in rodents possess predictive
validity for human craving for alcohol (see Markou et al., 1993),
these data bear translational relevance. In terms of translation
“from lab bench to bedside,” it may be worth noting that baclofen
resulted to be more potent and effective in those rats (either
selectively bred or made physically dependent on alcohol) seek-
ing and taking larger amounts of alcohol (Walker and Koob,
2007; Maccioni et al., 2012). This view shares some similarities
with clinical data. Indeed, as stated below, the hypothesis that
baclofen may be more effective in patients affected by severe
forms of AUD has been advanced to reconcile the discrepancy
observed among some clinical surveys: surveys recruiting patients
affected by severe alcohol dependence provided stronger evidence
on the suppressing effect of baclofen on alcohol craving and con-
sumption than those studies including individuals affected by
moderate AUD.
When investigated, the selectivity of the reducing effect of
baclofen on alcohol self-administration was relatively modest, as
treatment with baclofen tended to also reduce self-administration
of and ER for sucrose or saccharin solutions or regular food
pellets (used as alternative, non-drug reinforcers) with magni-
tude comparable to that observed in the “alcohol” experiments
(Anstrom et al., 2003; Colombo et al., 2003b; Janak and Gill, 2003;
Maccioni et al., 2005, 2008b, 2012).
Reinstatement of alcohol-seeking behavior
Operant procedures of alcohol self-administration can be prof-
itably used also for studies of reinstatement of alcohol-seeking
behavior. In this procedure, previously extinguished, unrein-
forced lever-responding for alcohol is resumed—or reinstated—
by alcohol-related stimuli, alcohol itself, stressors, or drugs such
as nicotine and cannabinoids. Reinstatement of alcohol-seeking
behavior represents an experimental model of loss of control
over alcohol and relapse episodes occurring in alcohol-dependent
patients (see Martin-Fardon and Weiss, 2013). In agreement with
the results of the ADE experiments (see above), acute treatment
with baclofen (3mg/kg, i.p.) markedly reduced lever-responding
in sP rats initially trained to lever-respond for alcohol under
an FR4 schedule of reinforcement, then subjected to an ER
phase, and finally to a single reinstatement session in which
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lever-responding was effectively reinstated by presentation of an
alcohol-associated stimulus complex (Maccioni et al., 2008a).
A recent study (Duke et al., 2014) has generated the first set of
data on the “anti-alcohol” effects of baclofen in non-human pri-
mates, providing a powerful translational bridge between rodent
and human studies. Adult, male baboons were trained under a
chained schedule of reinforcement, made by three linked com-
ponents: sequential completion of the RR of each component
ultimately resulted in availability of oral alcohol (4%, w/v). Acute,
intramuscular injection of baclofen (1.8–2.4mg/kg) produced
significant decrements in lever-responding for alcohol, number
of alcohol drinks, and amount of self-administered alcohol. An
additional experiment found that baclofen also decreased lever-
responding in a single ER session. As in most rodent studies,
selectivity was relatively modest, as baclofen reduced the self-
administration of an alternative, non-drug reinforcer (orange-
flavored beverage) with limited dose separation in comparison
to the “alcohol” experiments. Nevertheless, these results extend
to non-human primates the capacity of baclofen to attenuate the
reinforcing effects of alcohol.
Alcohol stimulating and rewarding effects
Beside the several, above-mentioned studies on baclofen effect
on alcohol-seeking and taking behaviors, additional rodent stud-
ies have investigated the effect of treatment with baclofen on
other alcohol-related responses and behaviors. Specifically, it has
been reported that acute administration of 1–3mg/kg baclofen
(i.p.) suppressed the stimulation of locomotor activity induced in
alcohol-preferring UChB (Quintanilla et al., 2008) and unselected
Sprague-Dawley (Arias et al., 2009) rats and mice belonging to
different strains/lines (including NMRI, BALB/c, DBA/2J, and
selectively bred FAST) (Cott et al., 1976; Humeniuk et al., 1993;
Shen et al., 1998; Broadbent and Harless, 1999; Chester and
Cunningham, 1999; Boehm et al., 2002; Holstein et al., 2009)
by treatment with low-to-moderate doses of alcohol. These data
are of relevance, as locomotor stimulation induced by a psy-
choactive drug, including alcohol, has been proposed to model
its euphorigenic properties. Hyperlocomotion in rats and mice,
and stimulation and euphoria in humans are indeed homologous
phenomena, mediated by activation of common neural systems
(see Wise and Bozarth, 1987). Baclofen capacity to suppress
alcohol-stimulated locomotor activity in rodents may therefore
be predictive of a suppressant effect on alcohol stimulating and
euphorigenic actions in humans.
Acute microinjection of non-sedative doses of baclofen into
the VTA suppressed alcohol-induced conditioned place prefer-
ence in mice (Bechtholt and Cunningham, 2005); since condi-
tioned place preference is a behavioral technique validated to
investigate the rewarding properties of psychoactive drugs (see
Tzschentke, 2007), these data suggest that pharmacological acti-
vation of the GABAB receptor may suppress alcohol “reward.”
Hypotheses on the mechanism(s) of action
In terms of the mechanism(s) of action underlying the “anti-
alcohol” effects of baclofen, data collected to date suggest the
involvement of (a) GABAB receptors located in the VTA both
pre-synaptically (on the cell body of dopamine neurons) and
post-synaptically (on the terminals of glutamatergic afferent neu-
rons) (see Bowery et al., 1987) and (b) the mesolimbic “reward”
dopamine system, whose neurons originate in the VTA, project
into the nucleus accumbens (NAc), and mediate the reinforcing,
motivational, stimulating, and rewarding properties of alcohol
(see Weiss and Porrino, 2002). This hypothesis is based on sev-
eral lines of experimental evidence demonstrating that acute
microinjections of non-sedative doses of baclofen into the VTA
suppressed: (a) alcohol binge-like drinking in mice (Moore and
Boehm, 2009); (b) alcohol-seeking behavior in rats (Leite-Morris
and Czachowski, 2006; Leite-Morris et al., 2008); (c) alcohol-
induced stimulation of dopamine release in the rat NAc (K.A.
Leite-Morris, personal communication); (d) alcohol-stimulated
locomotor activity in mice (Boehm et al., 2002; Leite-Morris,
2004); (e) alcohol-induced place preference in mice (Bechtholt
and Cunningham, 2005). Together, these results suggest that acti-
vation of the GABAB receptors in the VTA results in inhibition
of alcohol-induced firing of dopaminergic neurons, alcohol-
stimulated dopamine release in the NAc, and—in turn—multiple
dopamine-controlled, alcohol-related responses and behaviors.
Alcohol withdrawal syndrome
Several studies demonstrated that treatment with baclofen (1.25–
20mg/kg, i.p.) was also effective in suppressing multiple signs
of AWS, including (a) increase in alcohol self-administration in
Wistar rats made alcohol-dependent by prolonged exposure to
alcohol vapors (Walker and Koob, 2007), suggesting the ability of
baclofen to suppress the negative reinforcing properties of alco-
hol, (b) anxiety-related behaviors in Lister and Sprague-Dawley
rats made alcohol-dependent by prolonged, forced exposure to an
alcohol-containing diet (File et al., 1991; Knapp et al., 2007), and
(c) tremors and seizures in Wistar rats made alcohol-dependent
by the repeated administration of intoxicating amounts of alco-
hol (Colombo et al., 2000). As detailed below, these data depicting
the capacity of baclofen to suppress multiple signs of AWS in rats
have found a remarkable translational potential in several clini-
cal studies. In terms of the mechanism(s) of action, activation of
the GABAB receptors likely counterbalances the enhanced func-
tion of glutamate excitatory neurotransmission associated to AWS
(Colombo et al., 2000; Knapp et al., 2007).
POSITIVE ALLOSTERIC MODULATORS
Alcohol drinking
Virtually all studies conducted to date demonstrate that the “anti-
alcohol” effects of baclofen and other GABAB receptor agonists
may be reproduced by treatment with the currently available,
in vivo effective GABAB PAMs (namely, CGP7930, GS39783,
BHF177, rac-BHFF, and ADX71441). Specifically, repeated (once
daily for 5–7 consecutive days) treatment with CGP7930 (25–
100mg/kg, i.g.), GS39783 (6.25–100mg/kg, i.g.), and rac-BHFF
(50–200mg/kg, i.g.) has been reported to reduce daily alco-
hol intake in sP rats exposed to the 2-bottle “alcohol vs water”
choice regimen (Orrù et al., 2005; Loi et al., 2013); daily
water intake was compensatorily increased, leading to exclude
that reduction in alcohol drinking was secondary to sedation.
More recently, acute treatment with ADX71441 (3–30mg/kg,
i.g.) reduced alcohol intake in C57BL/6J mice exposed to (a)
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a model of excessive alcohol drinking based on the intermit-
tent access, once every other day, to 20% (v/v) alcohol [this
procedure is known to powerfully generate daily intakes of alco-
hol larger than 20 g/kg in C57BL/6J mice (Hwa et al., 2011)],
and (b) the DID model of binge-like drinking (Hwa et al.,
2014). Complete suppression of binge-like drinking generated
in C57BL/6J mice by the DID model was also observed after
acute treatment with 30mg/kg GS39783 (i.p.) (Linsenbardt and
Boehm, 2013).
Operant self-administration of alcohol
Several, recent studies have investigated the effect of GABAB
PAMs on operant, oral alcohol self-administration in alcohol-
preferring rats. An initial study found that acute treatment with
CGP7930 (10 and 20mg/kg, i.p.) reduced lever-responding for
alcohol in P rats exposed to an FR3 schedule of reinforce-
ment (Liang et al., 2006). Subsequent studies, conducted with
sP rats exposed to an FR4 schedule of reinforcement, reported
the capacity of GS39783 (25–100mg/kg, i.g.) (Maccioni et al.,
2007), BHF177 (12.5–50mg/kg, i.g.) (Maccioni et al., 2009),
and rac-BHFF (50–200mg/kg, i.g.) (Maccioni et al., 2010)—
given under a Latin square design—to reduce lever-responding
for alcohol. In the few studies in which baclofen and GABAB
PAMs were concurrently tested (Liang et al., 2006; Maccioni
et al., 2012), baclofen resulted to be more potent and effec-
tive in reducing lever-responding for alcohol; however, at vari-
ance with the results collected with baclofen, the reducing effect
of GS39783, BHF177, and rac-BHFF (at least within a given
dose-range for the latter compound) displayed the important
feature of being highly selective for alcohol self-administration:
indeed, treatment with these compounds did not alter lever-
responding for a sucrose solution in independent sets of sP rats.
Additional studies are needed to understand the bases of the
differential selectivity of the “anti-alcohol” effects of baclofen
and GABAB PAMs; nevertheless, these “selectivity” data are in
close agreement with the results of several studies (Cryan et al.,
2004; Malherbe et al., 2008; Paterson et al., 2008) suggesting the
capacity of GABAB PAMs to produce the “desired” behavioral
effects—anxiolysis or “anti-addictive” effects—at doses far lower
than those inducing motor-impairment and sedation, display-
ing higher therapeutic index and better side-effect profile than
baclofen.
When tested in experiments of PR schedule of reinforce-
ment, GS39783 (25-100mg/kg, i.g.) (Maccioni et al., 2008b)
and BHF177 (12.5–50mg/kg, i.g.) (Maccioni et al., 2009)—
given under a Latin square design—reduced lever-responding
and breakpoint for alcohol in sP rats. Again, the reducing effect
of both compounds was fully selective for alcohol, as no dose
altered—even minimally—breakpoint for a sucrose solution.
A more recent study (Maccioni et al., 2012) compared the
effect of GS39783 on alcohol self-administration in P, sP, and
AA rats exposed to identical FR4 and PR schedules of rein-
forcement for alcohol: although treatment with GS39783 reduced
number of lever-responses, amount of self-administered alcohol,
and breakpoint in all rat lines, potency and efficacy of GS var-
ied largely among the three lines, being highest in those rats (P
line) in which alcohol displayed the strongest reinforcing and
motivational properties and lowest in those rats (AA line) in
which alcohol was less reinforcing andmotivating. If ideally trans-
lated to humans, these data would suggest that GS39783 is more
effective in those patients affected by severe forms of AUD.
A recent, confirmatory study reported the capacity of acutely
administered BHF177 (3.75–30mg/kg, i.p.) to reduce self-
administration of a beer-like mixture, containing 9% alcohol, in
C57BL/6J mice trained to lever-press under an FR3 schedule of
responding (Orrù et al., 2012).
CLINICAL DATA
BACLOFEN AND ALCOHOL WITHDRAWAL SYNDROME
Clinical management of AWS is aimed at (a) reducing the sever-
ity of symptoms, (b) preventing more severe manifestations, such
as seizures and delirium tremens, and (c) facilitating patient’s
admission into treatment programs to maintain long-term absti-
nence (Hall and Zador, 1997; Mayo-Smith, 1997). Clinical eval-
uation of AWS symptoms can be performed by means of several
scales, including the Clinical Institute Withdrawal Assessment for
Alcohol-revised scale (CIWA-Ar) (Mayo-Smith, 1997). This scor-
ing system allows a quantitative evaluation of AWS severity and
enhances identification of subjects potentially requiring phar-
macological treatment. In addition to administration of fluids,
thiamine, and electrolytes, benzodiazepines represent the current
drugs of choice in the treatment of AWS (Amato et al., 2010,
2011). However, benzodiazepines may feature addictive prop-
erties, representing a major limitation to their use in subjects
affected by AUD (Leggio et al., 2008).
Preliminary data based on case reports (Addolorato et al.,
2002a, 2003), retrospective chart review (Stallings and Schrader,
2007), and randomized-controlled trials (Addolorato et al., 2006;
Lyon et al., 2011) support the effectiveness of baclofen in the
treatment of AWS in humans.
Case reports
A first study showed that baclofen administration rapidly sup-
pressed symptoms of severe AWS (Addolorato et al., 2002a). In
this study, 5 patients (4 men and 1 woman; mean daily drinks:
24; mean CIWA-Ar score: 27) were treated with relatively low oral
doses of baclofen, equal to 30mg/day [10mg, administered three
times a day (t.i.d.)], and AWS severity was evaluated every hour
for 4-8 hours. After baclofen administration, all 5 patients showed
a rapid decrease in CIWA-Ar scores and a rapid improvement
of well-being. Patients were maintained at 30mg/day baclofen,
during a 30-day follow-up period, and all maintained abstinence
without reporting significant side effects.
Addolorato et al. (2003) also reported the ability of 75mg/day
baclofen (25mg t.i.d.) to stop delirium tremens, the most severe
complication of AWS. Namely, a single baclofen administra-
tion decreased CIWA-Ar score below 8 within 1 h in a patient
with severe AWS, complicated by delirium tremens. Effectiveness
was confirmed by a progressive normalization, within 4 days of
treatment, of biological markers of excessive alcohol consump-
tion (e.g.: GGT, AST, ALT, and MCV). Following stabilization,
baclofen dose was reduced to 30mg/day, and the patient main-
tained full abstinence from alcohol over the subsequent 30 days,
with no relevant side effects.
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Comparative studies
In a subsequent study, Addolorato et al. (2006) compared the
effectiveness of baclofen with benzodiazepines. Outpatients (18
subjects) were randomized to baclofen (30mg/day for 10 con-
secutive days) or diazepam (19 subjects; 0.5–0.75mg/kg/day for
6 consecutive days, and tapering of dose by 25% daily from day
7 to day 10). Both baclofen and diazepam significantly decreased
CIWA-Ar scores, with no differences between the two treatments.
However, evidence for recommending baclofen in the treatment
of AWS was considered insufficient by a recent Cochrane review
(Liu and Wang, 2011).
Retrospective studies
In a study carried out on data recorded at the Inpatient Medical
Centre, St. Anthony’s Hospital, Oklahoma City, Stallings and
Schrader (2007) found that administration of baclofen pre-
vented the development of symptoms of AWS in 12 cases
out of 17. However, no detail was provided as to the
dosage used.
Randomized, placebo-controlled studies
Finally, the results of a randomized, double-blind, placebo-
controlled trial also confirmed the effectiveness of baclofen in
reducing the intensity of AWS (Lyon et al., 2011). In this
study, 44 subjects with symptoms of AWS were randomized
to baclofen (30mg/day) or placebo, and all subjects received
symptom-triggered benzodiazepine treatments. Administration
of baclofen was associated with a significant reduction in the
use of benzodiazepines in the management of AWS over 72 h of
observation.
BACLOFEN TO ACHIEVE AND MAINTAIN ALCOHOL ABSTINENCE
Despite the promising results on AWS treatment, studies
conducted to date to evaluate its effectiveness in achiev-
ing and maintain abstinence have not achieved convergent
results.
Case reports
A series of case reports found that the administration of doses
of baclofen ranging from 75 to 400mg/day (divided into 3
daily administrations) markedly reduced or completely sup-
pressed alcohol intake in patients affected by AUD (Ameisen,
2005; Agabio et al., 2007; Bucknam, 2007; Dore et al., 2011).
Interestingly, one of these articles described the personal his-
tory of a French physician, who conducted an original dose-
finding curve with baclofen, with the aim of treating his own
AUD (Ameisen, 2005). After having used all the available AUD
medications (disulfiram, naltrexone, acamprosate, and topira-
mate), Dr. Olivier Ameisen tested oral baclofen, starting with
the “conventional” dose of 30mg/day. He then increased the
daily dose of baclofen up to 270mg (9 times higher than the
“conventional” dose), experiencing—“for the first time in my
alcoholic life”—complete abstinence and suppression of crav-
ing for alcohol. Because of somnolence, Ameisen progressively
reduced the baclofen dose to 120mg/day, adding 40mg in stress-
ful situations. This “maintenance” dose provided a complete
control of his alcohol craving without any particular side effect.
Ameisen also suffered from comorbid anxiety disorders, and the
120mg/day baclofen “maintenance” dose completely suppressed
anxiety. Other studies found that baclofen administration ame-
liorated anxiety in alcohol-dependent subjects suggesting that the
“anti-alcohol” effects of baclofen in patients affected by comorbid
anxiety disorders may be due, at least in part, to a relief of anxi-
ety symptoms (Krupitsky et al., 1993; Addolorato et al., 2002b;
Flannery et al., 2004; Garbutt et al., 2010).
Two of these case reports indicated that administration of high
doses of baclofen was effective also in patients affected by AUD
and other psychiatric illnesses, resistant to previous treatments
(Agabio et al., 2007; Dore et al., 2011). Notably, these patients did
not develop any side effects due to the combination of baclofen
and other psychoactive drugs (namely, paroxetine, haloperidol,
and benzodiazepines).
Observational studies
Two recent observational studies confirmed the effectiveness of
high doses of baclofen (up to 330mg/day; average effective dose:
147mg/day) in reducing alcohol consumption (de Beaurepaire,
2012; Rigal et al., 2012). Namely, at 3-month observation, one
study found that more than 80 out of 100 patients affected by
AUD and resistant to usual treatment reduced alcohol consump-
tion from the initial “high risk” to “low risk” or “moderate risk”
level; at 2-year observation, 60% of these patients were still at
“low risk” or “moderate risk” level (de Beaurepaire, 2012). The
second study found that, after 1 year of treatment with high
doses of baclofen, more than 80% of 132 patients initially clas-
sified as “high risk drinkers” were abstinent or reduced alcohol
consumption to “low risk” level (Rigal et al., 2012).
Open studies
Two open studies evaluated the effectiveness of a lower dose
of baclofen, equal to 30mg/day, in the treatment of AUD
(Addolorato et al., 2000; Flannery et al., 2004). Namely, the first
trial recruited 10 men with AUD, and lasted 4 consecutive weeks
(Addolorato et al., 2000); the second study recruited 12 sub-
jects with AUD (3 women and 9 men), and lasted 12 consecutive
weeks (Flannery et al., 2004). Both studies found that this dose
of baclofen effectively reduced daily drinking, episodes of heavy
daily drinking, and severity of craving for alcohol and anxiety.
However, in the second study, no patient achieved andmaintained
abstinence (Flannery et al., 2004).
Randomized, placebo-controlled studies
Two series of randomized clinical trials, conducted in Italy
and in the U.S., generated diverging results, using 30mg/day
baclofen (Addolorato et al., 2000, 2002b, 2007, 2011; Garbutt
et al., 2010). According to the findings of the Italian studies,
the oral administration of this dose of baclofen reduced alco-
hol consumption and craving for alcohol (Addolorato et al.,
2000, 2002b, 2007, 2011), while the American study yielded less
promising results (Garbutt et al., 2010). The first randomized,
placebo-controlled, double-blind trial was conducted in Italy, and
recruited 39 patients with AUD: 20 patients received baclofen
(30mg/day), and 19 patients received placebo (Addolorato et al.,
2002b). Treatment lasted 4 consecutive weeks, and patients
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received psychological counseling once a week. The results of
the study showed that baclofen treatment increased the num-
ber of patients displaying complete abstinence (14/20 and 4/19
in baclofen and placebo groups, respectively) and decreased
alcohol consumption in patients who did not achieve com-
plete abstinence [the number of daily drinks dropped from
18 (start of treatment) to less than 0.5 (end of treatment) in
the baclofen group; it changed from 10 (start of treatment)
to approximately 4 (end of treatment) in the placebo group].
Baclofen was also effective in reducing craving and anxiety
scores.
The second randomized, placebo-controlled, double-blind
trial was conducted in the U.S. (Garbutt et al., 2010). This study
recruited 80 patients with AUD: 40 patients (22 and 18 men
and women, respectively) received baclofen (30mg/day), and
40 patients (22 and 18 men and women, respectively) received
placebo. Treatment lasted 12 consecutive weeks, and patients
received psychological support 8 times during the 12-week treat-
ment. The results of this study showed that baclofen was not
effective in reducing alcohol consumption, achieving abstinence,
or reducing craving for alcohol. Conversely, baclofen treatment
was associated with a reduction in anxiety scores.
These divergent results have been attributed, at least in part,
to methodological differences between the two studies (e.g.: study
duration, type and frequency of psychological support, number of
women recruited) (Leggio et al., 2010). For instance, mean daily
drinks at the start of baclofen treatment was equal to approxi-
mately 14 and 7 in the Italian and U.S. studies, respectively. This
discrepancy indicates that the Italian study recruited patients with
more severe AUD than the study conducted in the U.S. These dif-
ferences suggest that baclofenmay bemore potent and effective in
the treatment of severe AUD, rather than moderate AUD (Leggio
et al., 2010).
This hypothesis could also explain the extremely high efficacy
of relatively low doses of baclofen found in subjects affected by
liver cirrhosis and AUD, in whom the severity of AUD was so
severe as to impede them from achieving abstinence despite the
liver disease (Addolorato et al., 2007). This randomized, placebo-
controlled, double-blind trial recruited 84 patients (61 men and
23 women): 42 patients received baclofen (30mg/day), and 42
patients received placebo, for 12 consecutive weeks. Patients
received psychological support counseling every week for the first
month, and then every 2 weeks. The results of this study showed
that baclofen treatment increased the number of patients achiev-
ing and maintaining complete abstinence (30/42 and 12/42 in
baclofen and placebo groups, respectively), the cumulative absti-
nence duration (defined as the number of cumulative days of
total abstinence: 63 and 31 days in baclofen and placebo groups,
respectively), and reduced alcohol-craving score.
Finally, a more recent randomized, placebo-controlled,
double-blind trial did not achieve the preplanned level of par-
ticipation (Addolorato et al., 2011). It was an international,
multi-center study aimed at evaluating the effectiveness of two
different doses of baclofen (30 and 60mg/day). Unfortunately,
due to methodological limitations, only the dataset collected in
Italy could be analyzed; it was found that baclofen induced a
dose-effect reduction of alcohol intake.
All together, the results obtained by randomized studies are
less promising than those obtained by case reports. Among the
several reasons that may have contributed to this discrepancy, the
difference in the dose of baclofen used seems to be one of the
most relevant. Namely, the majority of randomized trials used ¼
of the “maintenance” dose found to be concurrently effective and
safe by Ameisen in his dose-finding curve. It is possible that the
dose used by randomized trials was insufficient at least for certain
patients. Additional studies should be conducted to investigate
whether higher doses of baclofen may result in more satisfactory
results in the treatment of AUD, taking into account the typology
of patients (e.g., severe or moderate AUD), their gender, possible
comorbid mental disorders, and/or renal function (see below).
To summarize, the limited number of studies conducted and
the contrasting results obtained by these studies prevent the draw-
ing of any conclusions regarding baclofen effectiveness in the
treatment of AUD. However, nowadays in France an overwhelm-
ing number of patients affected by AUD ask for and receive high
doses of baclofen to treat their disorder (Gorsane et al., 2012;
Rolland et al., 2012, 2013; Pastor et al., 2013).
BACLOFEN AND OTHER SUBSTANCES OF ABUSE
Preclinical studies demonstrated that baclofen is effective in
reducing the severity of opioid withdrawal syndrome in rats and
mice; a single double-blind clinical trial, including 62 patients
affected by opioid withdrawal syndrome, confirmed these results
in humans (see Agabio et al., 2013). Conversely, despite a large
body of preclinical studies suggesting the capacity of baclofen to
reduce intravenous self-administration of cocaine, heroin, nico-
tine, and methamphetamine in rodents, clinical studies failed
to extend these findings to humans (see Vlachou and Markou,
2010). Only one randomized, placebo-controlled study found
that baclofen administration (80mg/day) reduced the daily num-
ber of cigarettes in 60 patients affected by nicotine use disorder;
conversely, four randomized, placebo-controlled studies found
that the administration of baclofen (60mg/day) failed to reduce
the use of cocaine, opioids, and methamphetamine in 160, 40,
and 88 patients, respectively, affected by substance use disorder
(see Agabio et al., 2013).
Once again, the different results obtained by preclinical and
clinical studies suggest that further studies are needed to investi-
gate whether higher doses of baclofen may result in more satisfac-
tory results in the treatment of substance use disorder from drugs
other than alcohol.
SAFETY PROFILE OF BACLOFEN
PHARMACOKINETICS
Baclofen is available in formulations intended for oral or intrathe-
cal administration. The latter route of administration is used
in the treatment of spasticity unresponsive to oral administra-
tion of baclofen (Dario and Tomei, 2004). The recommended
oral daily dose for baclofen ranges from 15 to 80mg, starting
from 15mg/day (5mg, t.i.d.), and gradually increasing 5mg t.i.d.,
every 3 days. Higher daily doses (up to 120mg/day) should only
be administered to hospitalized patients. After administration,
baclofen is rapidly absorbed and up to 80% of an oral dose is
excreted in the urine (related to creatinine clearance), with only
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a limited hepatic metabolism (Gerkin et al., 1986; Wuis et al.,
1989). These pharmacokinetic characteristics make baclofen the
ideal pharmacological treatment for alcoholic patients affected by
liver disease while it should be avoided in patients with impaired
renal function (Chen et al., 1997; Smith et al., 1999). Accordingly,
renal function should be carefully assessed prior to baclofen
administration (Agabio et al., 2013).
When administered in low or moderate doses, baclofen has
a short half-life (2–6 h) and needs 3–4 daily administrations to
maintain therapeutic effects (Lal et al., 2009). When adminis-
tered in higher doses or in patients with impaired renal function,
its half-life is longer, and lower daily administrations may be
required (Gerkin et al., 1986; Chen et al., 1997; Smith et al., 1999).
SIDE EFFECTS
The wide use of baclofen in the treatment of spasticity has under-
pinned the collection of information on its safety and side effects
(Dario and Tomei, 2004). Generally, side effects observed after the
administration of low or moderate doses of baclofen are mild and
transient and include sedation or somnolence, excessive weak-
ness, and vertigo (Agabio et al., 2013). Symptoms are rarely severe
and frequently subside or disappear with continued therapy.
Low doses of baclofen have also proved to be manageable and
safe to use in patients affected by AUD (Krupitsky et al., 1993;
Addolorato et al., 2000, 2002a,b, 2003, 2007, 2011; Flannery et al.,
2004; Garbutt et al., 2010). In these studies side effects were
tolerable, mild to moderate—also in patients affected by liver
cirrhosis—and no study reported the occurrence of a withdrawal
syndrome after baclofen suspension or craving for baclofen. As
sedation is the most common side effect associated to baclofen
treatment, the additive sedative effects of baclofen and alco-
hol may theoretically constitute a problem for patients who do
not achieve and maintain abstinence. However, no increase in
sedation has been observed in baclofen-treated patients who con-
tinued to drink (Flannery et al., 2004; Bucknam, 2007; Garbutt
et al., 2010; Rigal et al., 2012). The results of studies from two
laboratories confirmed this empirical observation (Evans and
Bisaga, 2009; Leggio et al., 2013). Taken together, these results
suggest that the administration of low doses of baclofen may be
considered safe even if subjects continue to drink.
Higher doses of baclofen are usually well tolerated if dosage
is increased as well as discontinued gradually. Abrupt interrup-
tion and withdrawal from baclofen treatment may lead to possible
onset of seizures, psychological symptoms, and hyperthermia
(Dario and Tomei, 2004). For instance, a case of withdrawal
delirium after baclofen discontinuation has been described in a
patient affected by AUD who had received 75mg/day baclofen
for 6 months (Nasti and Brakoulias, 2011). The risk of with-
drawal symptoms should be minimized by avoiding the abrupt
discontinuation of therapy, reducing the dose by 5mg, t.i.d.,
every 3 days, until termination of therapy under strict medical
supervision (Agabio et al., 2013).
Intoxication after oral administration of baclofen is due to
error of administration, attempted suicide or impaired renal
function, and symptoms may be constituted by nausea, hypo-
tonia, dizziness, respiratory depression, coma, seizures, cardiac
conduction abnormalities, and EEG abnormalities (Lee et al.,
1992; Dario and Tomei, 2004). Usually, the outcome of baclofen
intoxication is good and a complete recovery of patients has been
reported even after episodes of coma caused by the intrathe-
cal administration of very high doses of baclofen (Agabio et al.,
2013). Very few cases of voluntary abuse of baclofen have been
described, execpt for attempting suicide (Lee et al., 1992; Perry
et al., 1998; Weisshaar et al., 2012). To date, baclofen has not
displayed addictive properties in patients affected by AUD.
CONCLUSIONS
Several lines of experimental evidence consistently suggest that
treatment with the prototypic GABAB receptor agonist, baclofen,
is effective in suppressing multiple alcohol-related behaviors—
including excessive alcohol drinking, binge-like drinking, oper-
ant alcohol self-administration, reinstatement of alcohol-seeking
behavior, and conditioned place preference—in rats, mice, and
baboons exposed to experimental procedures modeling different
aspects of human AUD. Treatment with baclofen also suppressed
several signs of AWS in rats. Although still rather sporadic,
the clinical data currently available suggest that the majority of
these animal findings may be successfully extended to human
alcoholics. The majority of these surveys suggest indeed that
treatment with baclofen may promote abstinence and decrease
alcohol consumption, craving for alcohol, and severity of alcohol
withdrawal symptoms and signs, including delirium tremens, in
alcohol-dependent patients. Additional studies are now needed to
provide more definitive conclusions on the therapeutic potential
of baclofen, including the high-dose treatment option inspired by
Ameisen’s work. Interestingly, the capacity of baclofen to be effec-
tive on both ameliorating AWS and achieving abstinence from
alcohol is seen as a plus, since it may facilitate patients’ admis-
sion into a long-term program aimed at maintaining abstinence
without requiring a change of the pharmacological agent.
Finally, a major step forward in the pharmacology of the
GABAB receptor seems to be represented by GABAB PAMs.
Preclinical data collected to date, demonstrating the ability of
GABAB PAMs to reproduce the suppressive effects of baclofen
on several alcohol-related behaviors, together with their more
favorable safety profile, advocate the remarkable potential of this
new class of agents. Notably, some GABAB PAMs are currently
approaching clinical evaluation (Addex Therapeutics webpage),
leading to hypothesize that they might be tested, in a reasonably
short period of time, in human alcoholics.
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